Asahi Kasei Pharma will launch a grant for joint research or research development mainly on drug discovery seeds and technologies.
The call addresses representatives from research organizations and those from SMEs and start-ups who develop application-oriented technologies and/or processes. 10 tandems - consisting of one representative from the research sector and one from a SME…
Translation is the key focus at the Berlin Institute of Health (BIH). The aim is to transfer promising results from the laboratory to clinical practice, and to use observations from daily clinical routine as inspiration for new research ideas. For…
ProBioGen AG and Ceva Santé Animale announce the signature of an exclusive license agreement for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR® technology.
ProBioGen and Ceva have a long track record of…
The Bill & Melinda Gates foundation is inviting grant proposals for a Grand Challenges Explorations initiative: Innovations for Improving the Impact of Health Campaigns seeks innovative solutions that accelerate the improvement of coverage, reach,…
The second open call of L4MS targets application experiments (AE) developing new intralogistics solutions with mobile robots and the Industrial IoT platform OPIL for logistics (Open Platform for Innovations in Logistics).
The proposals should…
Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy
▪ Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals
▪ Clovis currently planning to file an IND for…
Researchers from Charité – Universitätsmedizin Berlin and the German Cancer Consortium (DKTK) have successfully solved a longstanding problem in the diagnosis of head and neck cancers. Working alongside colleagues from Technische Universität (TU)…
ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the GlymaxX® Technology. Under the terms of the agreement, Bayer will…
Eckert & Ziegler AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, has been given the manufacturing authorization for additional production lines for its Ge-68/Ga-68-generators (GalliaPharm®). The…
